SFCM
VRDN icon

Seven Fleet Capital Management’s Viridian Therapeutics VRDN Stock Holding History

Seven Fleet Capital Management’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-14,654
Closed -$456K – 138
2025
Q4 		$456K Buy
+14,654
New +$402K 0.31% 50

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Seven Fleet Capital Management's VRDN Position: Q1 2026 in Review

Seven Fleet Capital Management sold out of Viridian Therapeutics (VRDN) in Q1 2026, closing a stake of 14,654 shares — an estimated $456K sold.

Seven Fleet Capital Management first reported a position in VRDN in Q4 2025 and held it in 1 quarter. The position peaked at $456K in Q4 2025. 225 funds tracked by Wall St. Rank hold VRDN as of Q1 2026.

  • Seven Fleet Capital Management reported no remaining Viridian Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Seven Fleet Capital Management sold 14,654 Viridian Therapeutics shares in Q1 2026, an estimated $456K.
  • Seven Fleet Capital Management first reported a position in Viridian Therapeutics in Q4 2025 and held it in 1 quarter.
  • Seven Fleet Capital Management's Viridian Therapeutics position peaked at $456K in Q4 2025.
  • 225 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q1 2026.

Based on Seven Fleet Capital Management's 13F filing for Q1 2026, filed 15 May 2026.